0000310158FALSE00003101582026-10-092026-10-090000310158us-gaap:CommonStockMember2026-10-092026-10-090000310158mrk:A3.250NotesDue2032Member2026-10-092026-10-090000310158mrk:A2.500Notesdue2034Member2026-10-092026-10-090000310158mrk:A1.375Notesdue2036Member2026-10-092026-10-090000310158mrk:A3.500NotesDue2037Member2026-10-092026-10-090000310158mrk:A3.700NotesDue2044Member2026-10-092026-10-090000310158mrk:A3.750NotesDue2054Member2026-10-092026-10-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 18, 2026 (November 16, 2026)
 
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
 
New Jersey
1-6571
22-1918501
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S Employer Identification No.)

126 East Lincoln Avenue
Rahway
New Jersey
07065
(Address of principal executive offices)
(Zip Code)
 (Registrant’s telephone number, including area code) (908) 740-4000
 
Not applicable
(Former name, former address and former fiscal year, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
3.250% Notes due 2032MRK/32New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
3.500% Notes due 2037MRK/37New York Stock Exchange
3.700% Notes due 2044MRK/44New York Stock Exchange
3.750% Notes due 2054MRK/54New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 16, 2026, Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders. Mr. Glocer’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.


Item 9.01. Financial Statements and Exhibits.

    (d)    Exhibits

    Exhibit 99.1    Press release issued November 18, 2026

    Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.
Date: November 18, 2026
By:/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary